PTC124 as a Therapy for Non-Sense Mutation Mediated Cystic Fibrosis - Miller Langdon

Abstract

Funding Agency

Agency: National Institute of Health (NIH)
Institute: Food and Drug Administration (FDA)
Type: Research Project (R01)
Project #: 3R01FD003009-02S1
Application #: 7498547
Study Section: Special Emphasis Panel (ZFD1-OPD (01))
Program Officer: Ganti, Usha

Project Start: 2005-09-30
Project End: 2008-09-29
Budget Start: 2006-09-30
Budget End: 2008-09-29
Support Year: 2
Fiscal Year: 2007
Total Cost
Indirect Cost

Institution

Name: Ptc Therapeutics, Inc.
Department
Type
DUNS #: 124371951

City: South Plainfield
State: NJ
Country: United States
Zip Code: 07080

Related projects


NIH 2007 R01 FD	PTC124 as a Therapy for Non-Sense Mutation Mediated Cystic Fibrosis Langdon, Miller / Ptc Therapeutics, Inc.
NIH 2006 R01 FD	PTC124 as a Therapy for Non-Sense Mutation Mediated Cystic Fibrosis Langdon, Miller / Ptc Therapeutics, Inc.
NIH 2005 R01 FD	PTC124 as a Therapy for Non-Sense Mutation Mediated Cystic Fibrosis Langdon, Miller / Ptc Therapeutics, Inc.

Comments

Be the first to comment on Miller Langdon's grant